Trial Profile
To Evaluate Safety and Efficacy of Crizotinib in Patients with ALK-positive (+) advanced non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Dec 2015 New trial record